Breakdown | |||||
TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|
Income Statement | Total Revenue | ||||
4.52M | 4.05M | 6.04M | 2.49M | 0.00 | 42.62K | Gross Profit |
4.52M | 4.05M | 5.33M | 1.42M | -589.00K | 36.27K | EBIT |
-57.04M | -54.76M | -65.53M | -84.87M | -58.03M | -21.28M | EBITDA |
-54.34M | -52.79M | -64.83M | -88.59M | -58.03M | -21.00M | Net Income Common Stockholders |
-57.48M | -54.05M | -63.08M | -77.83M | -58.37M | -22.62M |
Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
26.38M | 58.51M | 39.46M | 90.93M | 94.96M | 24.04M | Total Assets |
51.79M | 82.44M | 64.55M | 108.63M | 105.76M | 27.38M | Total Debt |
6.83M | 32.50M | 6.94M | 6.37M | 3.31M | 2.49M | Net Debt |
-19.54M | -26.01M | -32.52M | -71.19M | -91.65M | -21.55M | Total Liabilities |
21.53M | 52.81M | 23.98M | 24.58M | 9.94M | 5.83M | Stockholders Equity |
30.26M | 29.63M | 40.56M | 84.05M | 95.82M | 21.55M |
Cash Flow | Free Cash Flow | ||||
-51.95M | -45.53M | -72.53M | -64.54M | -48.88M | -15.02M | Operating Cash Flow |
-50.90M | -42.14M | -62.05M | -60.08M | -47.94M | -14.71M | Investing Cash Flow |
-1.14M | -3.38M | 3.08M | -16.97M | -1.82M | -306.82K | Financing Cash Flow |
63.76M | 64.86M | 20.88M | 59.48M | 120.68M | 31.61M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
56 Neutral | $309.55M | ― | -248.97% | ― | 86.63% | 22.29% | |
54 Neutral | $248.61M | ― | 322.49% | ― | -30.66% | 36.48% | |
54 Neutral | $5.31B | 3.26 | -45.10% | 2.79% | 16.76% | 0.02% | |
48 Neutral | $327.10M | ― | -299.58% | ― | -99.35% | -260.33% | |
42 Neutral | $193.05M | ― | -44.21% | ― | ― | ― | |
41 Neutral | $301.52M | ― | -100.13% | ― | ― | -71.53% | |
33 Underperform | $262.97M | ― | -124.74% | ― | ― | -20.39% |
On June 5, 2025, Ocugen, Inc. held its 2025 Annual Meeting of Stockholders virtually, where key proposals were voted on, including the election of directors and the ratification of an independent public accountant. Additionally, Ocugen announced the signing of a binding term sheet for the license of its OCU400 modifier gene therapy for retinitis pigmentosa in Korea, which includes upfront fees, development milestones, and sales royalties. This agreement aligns with Ocugen’s strategy to partner with established companies to expand its reach in treating retinitis pigmentosa patients and is expected to enhance its market presence in Korea.
The most recent analyst rating on (OCGN) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on Ocugen stock, see the OCGN Stock Forecast page.
Ocugen, Inc. announced its participation in the Eyecelerator conference in Park City, Utah, on May 2, 2025, where it will present a new presentation. This event is significant for Ocugen as it provides an opportunity to engage with investors, analysts, and other stakeholders, potentially impacting its market presence and investor relations.